CRISPR Therapeutics AG (CRSP)
50.01
+0.76
(+1.54%)
USD |
NASDAQ |
Oct 19, 16:00
48.90
-1.11
(-2.22%)
After-Hours: 16:11
CRISPR Therapeutics Cash from Operations (Annual) : -345.01M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -345.01M |
| December 31, 2024 | -142.77M |
| December 31, 2023 | -260.38M |
| December 31, 2022 | -495.74M |
| December 31, 2021 | 538.97M |
| December 31, 2020 | -238.37M |
| Date | Value |
|---|---|
| December 31, 2019 | 56.68M |
| December 31, 2018 | -96.24M |
| December 31, 2017 | -70.09M |
| December 31, 2016 | -55.31M |
| December 31, 2015 | 59.43M |
| December 31, 2014 | -4.793M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.631B |
| Basilea Pharmaceutica AG | 74.76M |
| Santhera Pharmaceuticals Holding AG | -41.86M |
| BeOne Medicines Ltd. | 1.131B |
| Intellia Therapeutics, Inc. | -394.74M |